| San Diego Biotech Entrepreneurs, Innovation Lead to “Maturing” Ecosystem | Sarah de Crescenzo | 03/30/20 | San Diego |
| Sanofi Adds mRNA COVID-19 Vaccine Bet Through Translate Bio Alliance | Frank Vinluan | 03/27/20 | Europe |
| Equillium Continues Graft-Versus-Host Disease Trial, Pauses 2 Others | Sarah de Crescenzo | 03/27/20 | San Diego |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| Forge Inks Roche Deal For Antibiotic Aimed at Drug-Resistant Infections | Sarah de Crescenzo | 03/26/20 | San Diego |
| With $80M, ReCode Looks to Advance RNA Therapies for Lung Diseases | Sarah de Crescenzo | 03/26/20 | San Francisco |
| FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch | Frank Vinluan | 03/26/20 | New York |
| Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel | Sarah de Crescenzo | 03/26/20 | Boston |
| Regenacy Pharma Raises $30M for Nerve Function Restoring Treatments | Sarah de Crescenzo | 03/25/20 | Boston |
| AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics | Frank Vinluan | 03/25/20 | Europe |
| Kallyope Gains $112M to Move “Gut-Brain Axis” Programs to the Clinic | Sarah de Crescenzo | 03/25/20 | New York |
| CytomX Lands $80M to Kick Off Cancer Drug R&D Pact With Astellas | Frank Vinluan | 03/24/20 | San Francisco |
| Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing | Brenda Sandburg | 03/24/20 | National |
| Investors Shaken by Coronavirus Sow Seeds of M&A, Financing Slowdown | Sarah de Crescenzo | 03/23/20 | National |
| FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes | Frank Vinluan | 03/23/20 | Europe |
| Keros Outlines IPO Plans Amid Markets Rocked by Coronavirus Pandemic | Sarah de Crescenzo | 03/23/20 | Boston |
| UCSD, 5 Diagnostic Makers Partner to Ramp COVID-19 Testing Capacity | Sarah de Crescenzo | 03/20/20 | San Diego |
| Bio Roundup: Coronavirus Diagnostics, Therapeutics, Vaccines & More | Sarah de Crescenzo | 03/20/20 | National |
| Eureka Partners With Lyell to Tackle Tricky Solid Tumor Cell Therapies | Sarah de Crescenzo | 03/20/20 | San Francisco |
| As the Commercial Real Estate Market Slumps, Look for a More Tenant-Friendly Future | Editors | 03/19/20 | Boston |
| How San Diego Biotech Leaders Are Adapting to Coronavirus Concerns | Sarah de Crescenzo | 03/19/20 | San Diego |
| Fears Of Recession Mount As Coronavirus Declared A Pandemic | Andrew McConaghie | 03/19/20 | National |
| AbCellera’s Coronavirus “Neutralizing” Antibody Leads Enter Screening | Sarah de Crescenzo | 03/17/20 | National |
| Qiagen Juices RNA Extraction Kit Capacity to Feed Coronavirus Test Needs | Sarah de Crescenzo | 03/17/20 | National |
| The Benefits and Impact of Later In-Licensing Deals for Biopharma | Gareth Macdonald | 03/17/20 | National |
| Novo Nordisk Pauses 3 Clinical Trials Testing Hemophilia Therapy | Sarah de Crescenzo | 03/16/20 | Europe |
| UC San Diego Health Develops COVID-19 Test, Begins Testing Patients | Sarah de Crescenzo | 03/14/20 | San Diego |
| Lax Approval Requirements Yield Blockbusters That Don’t Work | Andy Smith | 03/13/20 | National |
| Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More | Frank Vinluan | 03/13/20 | National |
| Rubius Drops Rare Diseases, Turns to Cancer and Autoimmune Disorders | Sarah de Crescenzo | 03/12/20 | Boston |
